Changes in the intestinal microbiota of patients with Parkinson’s disease and their clinical significance
To investigate the differences and their clinical significance in the intestinal microbiota in patients with Parkinson's disease (PD) in comparison to those in healthy controls. 20 patients with PD who received treatment in the First Affiliated Hospital of Bengbu Medical College between January...
Saved in:
Published in | International journal of clinical pharmacology and therapeutics Vol. 61; no. 2; pp. 48 - 58 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG
01.02.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | To investigate the differences and their clinical significance in the intestinal microbiota in patients with Parkinson's disease (PD) in comparison to those in healthy controls.
20 patients with PD who received treatment in the First Affiliated Hospital of Bengbu Medical College between January 2019 and December 2019 were selected as the research subjects to form the PD group, while 20 age- and gender-matched healthy volunteers were selected as the control group. Fecal samples from the two groups were collected, and the V4 region of 16S-ribosomal ribonucleic acid was selected for high-throughput sequencing analysis to explore any differences, as well as their significance, in the intestinal microbiota abundance at the class, family, and genus levels between the two study groups.
The operational taxonomic unit cluster analysis revealed a high degree of overlap between the patients with PD and the controls. Compared with the controls, the relative abundance of
and
was increased in the PD group (p < 0.01), while the relative abundance of
was significantly lower (p < 0.01). The relative abundance of
,
, and
in the PD group was significantly higher than in the control group (p < 0.05).
Compared with the healthy subjects, the abundance of specific microflora was significantly different in the PD patients at the class, family, and genus level. Intestinal flora may act as a potential biomarker for PD and provide a theoretical basis for microflora transplantation therapy. |
---|---|
AbstractList | To investigate the differences and their clinical significance in the intestinal microbiota in patients with Parkinson's disease (PD) in comparison to those in healthy controls.OBJECTIVETo investigate the differences and their clinical significance in the intestinal microbiota in patients with Parkinson's disease (PD) in comparison to those in healthy controls.20 patients with PD who received treatment in the First Affiliated Hospital of Bengbu Medical College between January 2019 and December 2019 were selected as the research subjects to form the PD group, while 20 age- and gender-matched healthy volunteers were selected as the control group. Fecal samples from the two groups were collected, and the V4 region of 16S-ribosomal ribonucleic acid was selected for high-throughput sequencing analysis to explore any differences, as well as their significance, in the intestinal microbiota abundance at the class, family, and genus levels between the two study groups.MATERIALS AND METHODS20 patients with PD who received treatment in the First Affiliated Hospital of Bengbu Medical College between January 2019 and December 2019 were selected as the research subjects to form the PD group, while 20 age- and gender-matched healthy volunteers were selected as the control group. Fecal samples from the two groups were collected, and the V4 region of 16S-ribosomal ribonucleic acid was selected for high-throughput sequencing analysis to explore any differences, as well as their significance, in the intestinal microbiota abundance at the class, family, and genus levels between the two study groups.The operational taxonomic unit cluster analysis revealed a high degree of overlap between the patients with PD and the controls. Compared with the controls, the relative abundance of Coriobacteriia and Coriobacteriaceae was increased in the PD group (p < 0.01), while the relative abundance of Lachnospiraceae was significantly lower (p < 0.01). The relative abundance of Collinsella, Escherichia, and Fusobacterium in the PD group was significantly higher than in the control group (p < 0.05).RESULTSThe operational taxonomic unit cluster analysis revealed a high degree of overlap between the patients with PD and the controls. Compared with the controls, the relative abundance of Coriobacteriia and Coriobacteriaceae was increased in the PD group (p < 0.01), while the relative abundance of Lachnospiraceae was significantly lower (p < 0.01). The relative abundance of Collinsella, Escherichia, and Fusobacterium in the PD group was significantly higher than in the control group (p < 0.05).Compared with the healthy subjects, the abundance of specific microflora was significantly different in the PD patients at the class, family, and genus level. Intestinal flora may act as a potential biomarker for PD and provide a theoretical basis for microflora transplantation therapy.CONCLUSIONCompared with the healthy subjects, the abundance of specific microflora was significantly different in the PD patients at the class, family, and genus level. Intestinal flora may act as a potential biomarker for PD and provide a theoretical basis for microflora transplantation therapy. To investigate the differences and their clinical significance in the intestinal microbiota in patients with Parkinson's disease (PD) in comparison to those in healthy controls. 20 patients with PD who received treatment in the First Affiliated Hospital of Bengbu Medical College between January 2019 and December 2019 were selected as the research subjects to form the PD group, while 20 age- and gender-matched healthy volunteers were selected as the control group. Fecal samples from the two groups were collected, and the V4 region of 16S-ribosomal ribonucleic acid was selected for high-throughput sequencing analysis to explore any differences, as well as their significance, in the intestinal microbiota abundance at the class, family, and genus levels between the two study groups. The operational taxonomic unit cluster analysis revealed a high degree of overlap between the patients with PD and the controls. Compared with the controls, the relative abundance of and was increased in the PD group (p < 0.01), while the relative abundance of was significantly lower (p < 0.01). The relative abundance of , , and in the PD group was significantly higher than in the control group (p < 0.05). Compared with the healthy subjects, the abundance of specific microflora was significantly different in the PD patients at the class, family, and genus level. Intestinal flora may act as a potential biomarker for PD and provide a theoretical basis for microflora transplantation therapy. Objective: To investigate the differences and their clinical significance in the intestinal microbiota in patients with Parkinson’s disease (PD) in comparison to those in healthy controls.Materials and methods: 20 patients with PD who received treatment in the First Affiliated Hospital of Bengbu Medical College between January 2019 and December 2019 were selected as the research subjects to form the PD group, while 20 age- and gender-matched healthy volunteers were selected as the control group. Fecal samples from the two groups were collected, and the V4 region of 16S-ribosomal ribonucleic acid was selected for high-throughput sequencing analysis to explore any differences, as well as their significance, in the intestinal microbiota abundance at the class, family, and genus levels between the two study groups.Results: The operational taxonomic unit cluster analysis revealed a high degree of overlap between the patients with PD and the controls. Compared with the controls, the relative abundance of Coriobacteriia and Coriobacteriaceae was increased in the PD group (p < 0.01), while the relative abundance of Lachnospiraceae was significantly lower (p < 0.01). The relative abundance of Collinsella, Escherichia, and Fusobacterium in the PD group was significantly higher than in the control group (p < 0.05).Conclusion: Compared with the healthy subjects, the abundance of specific microflora was significantly different in the PD patients at the class, family, and genus level. Intestinal flora may act as a potential biomarker for PD and provide a theoretical basis for microflora transplantation therapy. |
Author | Yin, Liang Zhang, Li-Na Yuan, Wen-Ling Wang, Shi-Jie Ye, Ming |
Author_xml | – sequence: 1 givenname: Li-Na surname: Zhang fullname: Zhang, Li-Na – sequence: 2 givenname: Wen-Ling surname: Yuan fullname: Yuan, Wen-Ling – sequence: 3 givenname: Ming surname: Ye fullname: Ye, Ming – sequence: 4 givenname: Liang surname: Yin fullname: Yin, Liang – sequence: 5 givenname: Shi-Jie surname: Wang fullname: Wang, Shi-Jie |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36420886$$D View this record in MEDLINE/PubMed |
BookMark | eNplkT1OJDEQhR2Alp9diRMgSyQkA_7tbodoxAISEgS7ccvtrmYKeuzB9giRcY3NOAtH4SR4BAMSG1UFXz3Ve2-HbPjggZA9zo604up4ei2YEo3eINvMqGrCTaW3yE5Kt4wJrWvzg2zJSgnWNNU2Gacz628gUfQ0z6CMDCmjtyOdo4uhw5AtDcPL88JmBJ8TfcA8o9c23qFPwb8-_Uu0xwQ2AbW-X6lgpG5Ej66oJLzxOJTVO_hJNgc7Jvj1MXfJ39-nf6bnk8urs4vpyeXESc7zBDQI5cAKAKGN7OsKlNKdqTsmOwFDz3s9COuscJr3zEKlmtpJWXVSGWiU3CWH77qLGO6XxU87x-RgHK2HsEytqKWpFWdSFvTgG3oblrHYX1GVUYUzplD7H9Sym0PfLiLObXxs1zkW4OgdKJGlFGFoHeYSWPA5WhxbztpVOe26nK8XPw_Wmv-hbwzXkjs |
CitedBy_id | crossref_primary_10_3390_biomedicines11102658 |
ContentType | Journal Article |
Copyright | Copyright Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG 2023 |
Copyright_xml | – notice: Copyright Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG 2023 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
DOI | 10.5414/CP204285 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE ProQuest One Academic Middle East (New) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EndPage | 58 |
ExternalDocumentID | 36420886 10_5414_CP204285 |
Genre | Journal Article |
GroupedDBID | --- 36B 5GY 7X7 88E 8FI 8FJ AAYXX ABJNI ABUWG ACGFO ACGFS ADBBV AENEX AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS BENPR BPHCQ BVXVI CCPQU CITATION DLWAR EBS EJD EMB F5P FYUFA HMCUK M1P P2P PHGZM PHGZT PQQKQ PROAC PSQYO SJN UKHRP VDS ~4P .GJ 53G AFFNX CGR CUY CVF ECM EIF EMOBN MK0 NPM SV3 ZGI ZXP 3V. 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 |
ID | FETCH-LOGICAL-c311t-e5e24cea2ee2593d76e445b97b03b2efd1d5f2aca2c51d0ae6487c336b349e843 |
IEDL.DBID | 7X7 |
ISSN | 0946-1965 |
IngestDate | Fri Jul 11 00:02:53 EDT 2025 Fri Jul 25 04:12:01 EDT 2025 Thu Apr 03 07:02:38 EDT 2025 Tue Jul 01 01:26:44 EDT 2025 Thu Apr 24 23:10:24 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c311t-e5e24cea2ee2593d76e445b97b03b2efd1d5f2aca2c51d0ae6487c336b349e843 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 36420886 |
PQID | 2769497499 |
PQPubID | 2044854 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_2739741033 proquest_journals_2769497499 pubmed_primary_36420886 crossref_citationtrail_10_5414_CP204285 crossref_primary_10_5414_CP204285 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-02-01 2023-Feb 20230201 |
PublicationDateYYYYMMDD | 2023-02-01 |
PublicationDate_xml | – month: 02 year: 2023 text: 2023-02-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany – name: Munich |
PublicationTitle | International journal of clinical pharmacology and therapeutics |
PublicationTitleAlternate | Int J Clin Pharmacol Ther |
PublicationYear | 2023 |
Publisher | Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG |
Publisher_xml | – name: Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG |
SSID | ssj0025579 |
Score | 2.3572285 |
Snippet | To investigate the differences and their clinical significance in the intestinal microbiota in patients with Parkinson's disease (PD) in comparison to those in... Objective: To investigate the differences and their clinical significance in the intestinal microbiota in patients with Parkinson’s disease (PD) in comparison... |
SourceID | proquest pubmed crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 48 |
SubjectTerms | Biomarkers Clinical Relevance Clinical significance Feces - microbiology Gastrointestinal Microbiome Humans Microbiota Parkinson Disease - diagnosis Parkinson's disease |
Title | Changes in the intestinal microbiota of patients with Parkinson’s disease and their clinical significance |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36420886 https://www.proquest.com/docview/2769497499 https://www.proquest.com/docview/2739741033 |
Volume | 61 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8QwEA4-Ll7Et-uLEUQvFrdJk7YnUVFEUBZR2FtJkxRE7a52PXjzb_j3_CXOtOkugnpuSKAzk3zz-oaxPaULLnWhgkRQtCp1YZBYV6DFaxkjhEBQQr3D1zfq8j666su-D7hVvqyyvRPri9oODMXIj3is0gjBb5oeD18CmhpF2VU_QmOazRJ1GWl13J84XFJ6rr1IBcSc15DP0uDro7MeJ29B_nyO_sCY9VtzscDmPUiEk0aqi2zKlUtsv9ewTL8fwt2kaao6hH3oTfin35fZY9MxUMFDCQjvgBgh0JBpx-eHhndppGFQgOdUrYCCsUD9z3Ur2NfHZwU-cQO6tFAnE6DtoQQq-aACI9KXFXZ_cX53dhn4mQqBEWE4Cpx0PDJOc-fQ8RE2Vi6KZJ7GeVfk3BU2tLLg2mhuZGi72in0aIwQKhcoyCQSq2ymHJRunYGJE1s4k3Oh6IlD3CCtlXHcTdGw0Q_rsIP212bGE47T3IunDB0PEkLWCqHDdscrhw3Jxi9rtlrpZN7MqmyiFLjF-DMaCGU9dOkGb7QGIVcUdoXosLVGquNDhKLqgkRt_L_5JpujKfNNsfYWmxm9vrltxCKjfKdWuB02e3p-07v9BkJ24HI |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwEB6VcoAL4p-FAoME5dKoiR07yQEhVKi29Ed72Ep7C47tSBWQLWQrtDdeg5fgoXgSZuJkV0jAredYEyUznvnGnvkG4Lk2tVCm1lEu-bSq8EmUO1_TjjcqIwhBoIR7h49P9Pg0fT9Tsw34OfTCcFnl4BM7R-3mls_Id0Wmi5TAb1G8Pv8S8dQovl0dRmgEszj0y2-UsrWvDt6Sfl8Isf9uujeO-qkCkZVJsoi88iK13gjvCfpLl2mfpqoqsiqWlfC1S5yqhbFGWJW42HhNmN5KqStJn5KnkuRegasUeGNO9rLZOsFTquf2S3XETH2B7JYHbe_uTQRnJ-rP8PcPTNvFtv2bcKMHpfgmWNEt2PDNbdieBFbr5Q5O101a7Q5u42TNd728Ax9Dh0KLZw0SnERmoCDHwRI_nwWep4XBeY09h2uLfPiL3G_dtZ79-v6jxf6iCE3jsLu8wKFnE7nEhAua2D7vwuml_O17sNnMG_8A0Ga5q72thNQcUgmnKOdUlsUFORLK-0bwcvi1pe0JznnOxqeSEh1WQjkoYQTPVivPA6nHX9ZsDdop-23dlmsjJBGrx7Qh-ZbFNH5-wWsI4qVJLOUI7getrl4iNVcz5Prh_4U_hWvj6fFReXRwcvgIrvOE-1AovgWbi68X_jHhoEX1pDM-hA-Xbe2_ASQSHJA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Changes+in+the+intestinal+microbiota+of+patients+with+Parkinson%27s+disease+and+their+clinical+significance&rft.jtitle=International+journal+of+clinical+pharmacology+and+therapeutics&rft.au=Zhang%2C+Li-Na&rft.au=Yuan%2C+Wen-Ling&rft.au=Ye%2C+Ming&rft.au=Yin%2C+Liang&rft.date=2023-02-01&rft.issn=0946-1965&rft.volume=61&rft.issue=2&rft.spage=48&rft_id=info:doi/10.5414%2FCP204285&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0946-1965&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0946-1965&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0946-1965&client=summon |